FDA approves Eli Lilly's weight loss drug Zepbound for sleep apnea, expanding use in U.S.
20 December 2024 at 13:40
The agency's decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance coverage for the treatment.